SLC5A2 and heart failure: Interestingly, recent studies showed that inhibitors of the sodium-glucose cotransporter-2, used in the therapy of type 2 diabetes, have cardioprotective effects in heart failure related to the systemic activation of SIRT1 and probably to the induction of SIRT1 expression in the heart [42].